Drug intelligence / Profile preview

Shulifenxiao formula

Development stage
Preclinical
Lead developer
Beijing University of Chinese Medicine
Modality
Small Molecules
Administration
Oral
01

Overview

Shulifenxiao formula is a traditional Chinese herbal medicine regimen used as an alternative or adjunctive therapy for nephrotic syndrome, particularly in patients with refractory idiopathic membranous nephropathy (RIMN) and primary membranous nephropathy (PMN) who are resistant to corticosteroids and immunosuppressants. The formulation is considered a "clinical cocktail therapy" and has demonstrated efficacy in reducing proteinuria, increasing serum albumin levels, improving estimated glomerular filtration rate (eGFR), and achieving remission in clinical studies. It is often used alone or in combination with low-dose cyclophosphamide. The mechanism of action appears to involve immunomodulation and reduction of anti-phospholipase A2 receptor antibody titers[1][2][3][4]. The safety profile is favorable with few adverse effects reported.

Other names
Shuli Fenxiao formulaSLFX formula
02

Targets

PLA2R1 (Phospholipase A2 receptor 1)

Beyond the preview

Go deeper on Shulifenxiao formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shulifenxiao formula.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call